For Chico artist Dolores Mitchell, the scenes of Durham's rice fields and bird refuges near Durham and Richvale deserve a ...

Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

Roivant Sciences and Moderna Therapeutics, two of the most highly-funded and controversial companies in the biotechnology world, are headed for a collision course over medical technology. On Monday, ...

Arbutus maintained a strong financial position with $93.7 million in cash, cash equivalents and marketable securities as of September 30, 2025, compared to $122.6 million at the end of 2024. The ...

Moderna stock fell 11% on Wednesday after the vaccine maker lost a patent fight against Arbutus Biopharma. Arbutus jumped 103% following the ruling as it could lead to royalty payments from Moderna.

April 11 (Reuters) - A U.S. appeals court handed Moderna Inc (MRNA.O), opens new tab a win on Tuesday, affirming a decision to cancel an Arbutus Biopharma Corp (ABUS.O), opens new tab patent related ...

(Reuters) -Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus ...

Arbutus Biopharma Corporation announced promising data from a late-breaker poster presentation at the EASL Congress 2025, revealing that its treatment combining imdusiran, a RNAi therapeutic, with VTP ...